NOVN Novartis AG

151.24USD127.44 CHF · SWX+0.16%Mkt Cap: 286.36B USDP/E: 30.64

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to tre…

Institutional holders14 on file

Key Statistics

Company
Market Cap286.36B USD
Enterprise Value333.56B USD
Revenue (TTM)57.36B USD
Gross Profit42.98B USD
Net Income (TTM)13.98B USD
Revenue/Share30.10 USD
Last Price151.24 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees75.3K
CountryCH
SectorHealthcare
IndustryDrug Manufacturers - General
ISINCH0012005267
Valuation
P/E (Trailing)30.64
P/E (Forward)15.45
PEG3.60
EV/EBITDA11.68
EV/Revenue5.81
P/S4.21
P/B7.86
EPS (TTM)4.17 USD
EPS (Forward)8.27 USD
52W Range
118.0375% of range162.59
52W High162.59 USD
52W Low118.03 USD
Profitability
Gross Margin75.83%
Oper. Margin33.98%
EBITDA Margin41.95%
Profit Margin24.67%
ROE30.31%
ROA12.60%
ROIC21.41%
ROCE21.09%
Growth
Revenue Growth4.70%
Earnings Growth-68.80%
Cash Flow & Leverage
Operating CF19.14B USD
CapEx (TTM)3.90B USD
FCF Margin19.64%
FCF Yield3.93%
Net Debt39.44B USD
Net Debt/EBITDA1.64
Net Debt/FCF3.50
Balance Sheet
Debt/Equity0.77
Current Ratio0.88
Quick Ratio0.58
Book Value/Sh16.25 USD
Cash/Share4.70 USD
Dividends
Fwd Div Rate4.39 USD
Trail. Div Rate5.54 USD
Div. Yield2.91%
5Y Avg Yield3.50%
Payout Ratio87.07%
Ex-Div DateMar 10, 2026
Pay DateMar 13, 2025
Splits
Last Split40:1
Split DateMay 7, 2001
Analyst Consensus
Rating2.8 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)152.83 USD
Upside (mean)+1.1%
Target Range121.62 USD – 183.37 USD
121.62+1.1% to mean183.37
# Analysts22
Ownership
Shares Out.1.89B
Float1.84B
Insiders2.11%
Institutions46.37%
Technical
SMA 50147.66 (+2.4%)
SMA 200145.47 (+4.0%)
Beta0.45
S&P 52W Chg8.68%
Avg Vol (30d)3.48M
Avg Vol (10d)3.09M
Technical Indicators
RSI (14)44.8
MACD1.3956
MACD Signal2.4492
MACD Hist.-1.0537
BB Upper162.84 USD
BB Middle156.69 USD
BB Lower150.53 USD
BB Width7.85%
ATR (14)3.107 USD
Vol Ratio (20d)1.17x

About Novartis (SWX: NOVN)

›

Novartis (SWX: NOVN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 75,267 employees.

The shares were at 127.44 CHF on 20 November 2026, up 25.7% over 52 weeks. Its 52-week range is 99.45 CHF to 137.00 CHF: the price is 7.0% below the high and 28.1% above the low.

At a market capitalisation of 241.29B CHF, it trades at 30.6 times trailing earnings and 15.5 times forward earnings. The median trailing P/E of its 18 largest Drug Manufacturers - General peers is 25.2, a premium of 22% for NOVN. It pays a dividend yielding 2.91% (it pays out 87% of its earnings), against a median of 2.45% among the dividend payers in that peer group.

Novartis reports return on equity of 30.3%, an operating margin of 34.0% and revenue up 4.7% year over year.

Its debt exceeds its cash by 39.44B USD, a debt-to-equity ratio of 0.77. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 22 analysts cover the stock, with an average rating of Hold; their mean price target of 128.78 CHF is 1.1% above the current price. The next earnings report is expected on 3 February 2027.